Articles from Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the appointment of Dennis Dean, Ph.D., as Executive Vice President and Head of Non-Clinical Development.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the appointment of Nia Tatsis, Ph.D., to its board. Dr. Tatsis is currently Executive Vice President and Chief Regulatory and Quality Officer of Vertex Pharmaceuticals and brings more than 20 years of experience in regulatory affairs and quality assurance.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today announced the closing of a $213 million Series D financing. In addition to participation from all existing investors, new investors included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners. Proceeds will support the advancement of Odyssey’s portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the appointment of Jason Haas, MBA, as chief financial officer (CFO).

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, and Terray Therapeutics, Inc., a biotechnology company focused on improving human health by transforming the speed, cost, and success rate of small molecule drug development using computation integrated with novel data at scale, announced today that they have entered into a strategic collaboration to jointly discover and develop small molecule medicines against transcription factor targets of interest. The collaboration combines Odyssey’s expertise in immunology and transcription factor biology with Terray’s complementary expertise in immunology and integrated AI platform, tNova, which leverages proprietary experimental data at scale to power its AI capabilities. Together, the companies will work to develop first-in-class therapeutic candidates for high-interest targets with potential application across inflammatory diseases.

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced that new translational data for its receptor-interacting protein kinase 2 (RIPK2) scaffolding inhibitor product candidate, OD-07656, will be presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held October 25-30, 2024.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators for inflammatory diseases, today announced the appointment of two Directors to its Board: Timothy P. Walbert, former Chairman, President and Chief Executive Officer (CEO) of Horizon Therapeutics, and Ian F. Smith, senior advisor at Bain Capital Life Sciences and former Executive Vice President and Chief Operating Officer (COO) of Vertex Pharmaceuticals. Together, these individuals have decades of senior leadership experience in building global biopharmaceutical companies.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators for inflammatory diseases, today announced the formation of its Scientific Advisory Board (SAB), which includes renowned experts in the fields of immunology and therapeutic development. The SAB will be chaired by Stephen Blacklow, M.D., Ph.D., who holds positions at Harvard Medical School and the Dana- Farber Cancer Institute and is a recognized drug discovery innovator.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators for autoimmune and inflammatory diseases, today announced the appointment of William Roush, Ph.D., as executive vice president and head of small molecule research. In this role, Dr. Roush will be responsible for overseeing the prosecution of Odyssey’s small molecule, preclinical portfolio from target selection into early development.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets. The companies will combine their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets. The agreement was facilitated by Johnson & Johnson Innovation.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Julie Clauss, MBA, as chief operating officer and Christopher Butler, Ph.D., as senior vice president (SVP), head of Chemistry. Together, these individuals bring more than 40 years of leadership experience and scientific expertise within the biotechnology and pharmaceutical industries to Odyssey.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the closing of a $101 million Series C financing round led by Ascenta Capital with participation from new and existing investors, including OrbiMed, SR One, General Catalyst, Foresite Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures, BlackMars Capital GmbH, Creacion Ventures, funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, Racing Beach Ventures LLC, The Healthcare Innovation Investment Fund LLC, an investment fund associated with Leerink Partners, Ab Magnitude Ventures, KB Investment, The Global BioAccess Fund, and multiple leading global investors. This Series C financing brings the total capital raised since founding in late 2021 to $487 million. Proceeds will support the advancement of multiple programs into clinical studies and the continuation of investment in discovery to build a sustainable model for therapeutic innovation.

Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, today announced the appointment of Jeremy Sokolove, M.D., as chief medical officer. In this role, Dr. Sokolove will develop, lead and drive the development strategy and execution of all Odyssey’s clinical assets. Additionally, he will be responsible for selecting, prioritizing and accelerating the company’s entire drug development portfolio.